Login
$ATYR
$5.24 +$0.00 (0.0%) After hours

$ATYR 8-K/A SEC Filings

Filed On Filing
08 Aug 2025 8-K/A: Results of Operations and Financial Condition

Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025.

14 Apr 2022 8-K/A: Other Events

On April 12, 2022, the U.S. Food and Drug Administration granted aTyr Pharma, Inc. orphan drug designation for its lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis (SSc, also known as scleroderma).

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support